Trade names Viberzi
Oral agent.
Protein binding 81%
Biological half-life 3.7–6 hours
Excretion in feces in 82.2% and <1% in urine.
Orally-active drug approved for the treatment of diarrhea and abdominal pain in individuals with diarrhea-predominant irritable bowel syndrome (IBS-D).
A μ- and κ-opioid receptor agonist and δ-opioid receptor antagonist that acts locally in the enteric nervous system, possibly decreasing adverse effects on the central nervous system.
An orally administered μ-opioid and κ-opioid receptor agonist and δ-opioid receptor antagonist indicated for the treatment of adults with IBS-D, is believed to slow GI tract motility and improve abdominal pain.
An orally administered μ-opioid and κ-opioid receptor agonist and δ-opioid receptor antagonist indicated for the treatment of adults with IBS-D, slows GI tract motility and improve abdominal pain.
Available as 75 and 100 mg in the form of tablets.
The most common adverse events include constipation (8.0%), nausea (7.7%), abdominal pain (6.5%), upper respiratory tract infection (4.4%), and vomiting (4.1%).
Associated with an increased risk of pancreatitis, with some occurrences associated with severe outcomes in some patients who had cholecystectomy.
Cholecystectomy, along with a history of sphincter of Oddi dysfunction, pancreatitis, and alcohol use (> 3 beverages per day) are contraindications for its use.
Use may lead to constipation.
Should be discontinued if the constipation lasts for more than 4 days.
Elevated concentrations of eluxadoline with coadministraion with:
Cyclosporine
Gemfibrozil
Certain antiretrovirals
Rifampin
Eltrombopag
Concurrent use of other drugs that cause constipation increases the problem.
Common adverse effects are constipation and nausea.
Rare adverse effects include: fatigue, bronchitis, viral gastroenteritis and pancreatitis.
Drug contraindicated with blockage of the gallbladder or a sphincter of Oddi problem, alcohol abuse, pancreatitis, liver disease, chronic or severe constipation.